Vmbook Online ordering

Mylan Inc

Mylan N.V. is a global pharmaceutical company headquartered in Hertfordshire, United Kingdom, and based in Canonsburg, Pennsylvania, United States, that develops, manufactures, markets, and distributes generic and branded pharmaceutical products. Mylan has a presence in approximately 165 countries and territories, including the United States, Canada, Australia, Japan, China, India, Russia, South Africa, and several countries in the Middle East and Europe.

Mylan was founded in 1961 by Milan Puskar and Dr. Ray Gilmartin as a small company in West Virginia, USA, called Sterling-Winthrop Research Institute. The company was renamed Mylan Laboratories in 1969 and went public in 1973. In the following decades, Mylan grew through a series of acquisitions, including the acquisition of Berlex Laboratories in 2007 and the merger with Merck KGaA's generics business in 2007.

Mylan's product portfolio includes a wide range of generic and branded pharmaceuticals, including products for the treatment of asthma, allergies, cardiovascular diseases, infectious diseases, neurological disorders, and other chronic conditions. Mylan's product portfolio includes both complex generic drugs and biosimilar products, which are follow-on versions of biologic drugs.

Mylan's stock is traded on the Nasdaq stock exchange under the symbol "MYL". As of February 2023, Mylan has a market capitalization of around $10 billion USD. Mylan's financial performance has been impacted by several factors in recent years, including increased competition, pricing pressures in the US market, and legal issues related to the company's EpiPen product.

Mylan is committed to increasing access to high-quality medicine, and the company's mission is to provide the best healthcare possible to the world's 7 billion people. Mylan's vision is to be the world's leading healthcare company, and the company is focused on delivering long-term value for its stakeholders, including patients, customers, employees, and investors.